Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL.

On Tuesday, December 3 at 12:55 PM ET, Drs. Swaminathan and Berman will participate in a fireside chat moderated by Evercore ISI’s Director of Biotechnology and Pharmaceuticals Michael DiFiore. Drs. Swaminathan and Berman will also be available for one-on-one meetings throughout the conference.

Investors can listen to the fireside chat by clicking here.

An archived webcast of the presentation will be available for one year on the “Events and Presentations” tab of the Coya Therapeutics website.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (“Tregs”) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 – the Company’s lead biologic investigational product or “Pipeline in a Product” – is a proprietary combination of COYA 301 (Coya’s proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.

For more information about Coya, please visit www.coyatherapeutics.com.

Forward-Looking Statements

This press release contains “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or will occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor

David Snyder, CFO

[email protected]

CORE IR

Bret Shapiro

[email protected]

561-479-8566

Media

For Coya Therapeutics:

Kati Waldenburg

[email protected]

212-655-0924

KEYWORDS: Florida Texas United States North America

INDUSTRY KEYWORDS: Health Neurology Genetics Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Diana Shipping Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2024; Declares Cash Dividend of $0.01 Per Common Share for the Third Quarter 2024

ATHENS, Greece, Nov. 25, 2024 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported net income of $3.7 million and a net income attributed to common stockholders of $2.3 million for the third quarter of 2024. This compares to net income of $7.4 million and net income attributed to common stockholders of $5.9 million for the third quarter of 2023. Earnings per share for the third quarter of 2024 was $0.02 basic and $0.00 diluted, compared to earnings per share of $0.06 basic and diluted in the same quarter of 2023.

Time charter revenues were $57.5 million for the third quarter of 2024, compared to $62.1 million for the same quarter of 2023. The decrease in time charter revenues, compared to the same quarter last year, was due to decreased average charter rates and ownership days.

Net income for the nine months ended September 30, 2024, amounted to $3.0 million and net loss attributed to common stockholders amounted to $1.3 million. This compares to net income of $40.5 million and net income attributed to common stockholders of $36.1 million, for the same period of 2023. Time charter revenues for the nine months ended September 30, 2024 were $171.1 million, compared to $202.1 million in the same period of 2023. Loss per share was $0.01 basic and diluted, compared to earnings per share of $0.36 basic and diluted in the nine months ended September 30, 2023.

Dividend Declaration

The Company has declared a cash dividend on its common stock of $0.01 per share, based on the Company’s results of operations during the third quarter ended September 30, 2024. The cash dividend will be payable on December 18, 2024 to all common shareholders of record as of December 11, 2024. The Company currently has 125,185,706 common shares issued and outstanding. As of November 19, 2024, there were 6,381,900 warrants exercised.

Fleet Employment (As of November 22, 2024)
                   
  VESSEL   SISTER SHIPS* GROSS RATE (USD PER DAY) COM** CHARTERERS DELIVERY DATE TO CHARTERERS*** REDELIVERY DATE TO OWNERS**** NOTES
  BUILT DWT  
9 Ultramax Bulk Carriers
1 DSI Phoenix   A 16,500 5.00 %   Bulk Trading SA 6-May-24 1/Aug/2025 – 30/Sep/2025  
  2017 60,456              
2 DSI Pollux   A 14,000 4.75 %   Cargill Ocean Transportation (Singapore) Pte. Ltd. 28-Dec-23 20/Aug/2025 – 20/Oct/2025  
  2015 60,446              
3 DSI Pyxis   A 14,250 5.00 %   ASL Bulk Marine Limited 24-Sep-23 8-Nov-24  
  2018 60,362     13,100 5.00 %   Stone Shipping Ltd 8-Nov-24 20/Feb/2026 – 20/Apr/2026  
4 DSI Polaris   A 13,100 5.00 %   ASL Bulk Marine Limited 12-Nov-22 20-Jul-24  
  2018 60,404     15,400 5.00 %   Stone Shipping Ltd 20-Jul-24 1/Jun/2025 – 15/Aug/2025  
5 DSI Pegasus   A 14,000 5.00 %   Reachy Shipping (SGP) Pte. Ltd. 7-Dec-22 5-Sep-24  
  2015 60,508     15,250 4.75 %   Cargill Ocean Transportation (Singapore) Pte. Ltd 5-Sep-24 1/Jun/2025 – 1/Aug/2025  
6 DSI Aquarius   B 14,500 5.00 %   Stone Shipping Ltd 18-Jan-24 5/Dec/2024 – 1/Feb/2025 1
  2016 60,309              
7 DSI Aquila   B 12,500 5.00 %   Western Bulk Carriers AS 11-Nov-23 30/Nov/2024 – 10/Jan/2025 1
  2015 60,309              
8 DSI Altair   B 13,800 5.00 %   Western Bulk Carriers AS 23-Jun-23 28-Sep-24  
  2016 60,309     15,750 5.00 %   Propel Shipping Pte. Ltd. 28-Sep-24 1/Nov/2025 – 31/Dec/2025  
9 DSI Andromeda   B 13,500 5.00 %   Bunge SA, Geneva 27-Nov-23 20/Feb/2025 – 20/Apr/2025 2
  2016 60,309              
6 Panamax Bulk Carriers
10 LETO     16,000 5.00 %   ASL Bulk Shipping Limited 3-May-24 1/Mar/2025 – 30/Apr/2025  
  2010 81,297              
11 SELINA   C 12,000 4.75 %   Cargill International S.A., Geneva 20-May-23 17-Oct-24  
  2010 75,700     10,500 5.00 %   Raffles Shipping International Pte. Ltd. 17-Oct-24 1/Mar/2025 – 20/Apr/2025  
12 MAERA   C 13,750 5.00 %   ST Shipping and Transport Pte. Ltd. 29-Jan-24 14/Dec/2024 – 20/Jan/2025 1
  2013 75,403              
13 ISMENE     12,650 5.00 %   Paralos Shipping Pte., Ltd. 13-Sep-23 15/Apr/2025 – 30/Jun/2025  
  2013 77,901              
14 CRYSTALIA   D 13,900 5.00 %   Louis Dreyfus Company Freight Asia Pte. Ltd. 4-May-24 4/Feb/2026 – 4/Jun/2026  
  2014 77,525              
15 ATALANDI   D 15,800 5.00 %   Quadra Commodities SA 28-May-24 20-Jul-24  
  2014 77,529     14,600 4.75 %   Cargill International SA, Geveva 20-Jul-24 1/Jun/2025 – 31/Jul/2025  
6 Kamsarmax Bulk Carriers
16 MAIA   E 13,500 5.00 %   ST Shipping and Transport Pte. Ltd. 23-Sep-23 30-Aug-24 3,4
  2009 82,193     13,000 5.00 %   Viterra Chartering B.V. 16-Sep-24 12-Dec-24 5
17 MYRSINI   E 17,100 5.00 %   Cobelfret S.A. Luxembourg 25-Jun-24 1/Feb/2025 – 25/Mar/2025  
  2010 82,117              
18 MEDUSA   E 14,250 5.00 %   ASL Bulk Shipping Limited 14-May-23 10/Feb/2025 – 15/Apr/2025  
  2010 82,194              
19 MYRTO   E 12,650 5.00 %   Cobelfret S.A., Luxemburg 15-Jul-23 24/Dec/2024 – 15/Jan/2025 1
  2013 82,131              
20 ASTARTE     15,000 5.00 %   Reachy Shipping (SGP) Pte. Ltd. 29-Apr-23 19-Aug-24  
  2013 81,513     14,000 5.00 %   Paralos Shipping Pte. Ltd. 19-Aug-24 15/Jul/2025 – 15/Sep/2025  
21 LEONIDAS P. C.     17,000 5.00 %   Ming Wah International Shipping Company Limited 22-Feb-24 20/Aug/2025 – 20/Oct/2025  
  2011 82,165              
5 Post-Panamax Bulk Carriers
22 ALCMENE     13,150 5.00 %   China Steel Express Corporation 1-Jun-24 11-Aug-24  
        13,350 5.00 %   11-Aug-24 30-Sep-24  
  2010 93,193     12,000 5.00 %   30-Sep-24 19-Nov-24 6
23 AMPHITRITE   F 15,000 5.00 %   Cobelfret S.A., Luxembourg 13-Jan-24 30/Nov/2024 – 15/Jan/2025 7,1
  2012 98,697              
24 POLYMNIA   F 17,500 5.00 %   Reachy Shipping (SGP) Pte. Ltd. 8-Jun-24 1/Aug/2025 – 30/Sept/2025  
  2012 98,704            
25 ELECTRA   G 14,000 4.75 %   Aquavita International S.A. 3-Jun-24 15/Oct/2025 – 31/Dec/2025  
  2013 87,150              
26 PHAIDRA   G 12,250 4.75 %   Aquavita International S.A. 9-May-23 12-Oct-24  
  2013 87,146     12,000 4.75 %   12-Oct-24 1/May/2025 – 15/Jul/2025  
8 Capesize Bulk Carriers
27 SEMIRIO   H 14,150 5.00 %   Solebay Shipping Cape Company Limited, Hong Kong 18-Aug-23 30/Nov/2024 – 30/Jan/2025 1
  2007 174,261              
28 HOUSTON   H 13,000 5.00 %   EGPN Bulk Carrier Co., Limited 21-Nov-22 2-Sep-24 8
  2009 177,729              
29 NEW YORK   H 16,000 5.00 %   SwissMarine Pte. Ltd., Singapore 11-Jun-23 29/Nov/2024 – 7/Dec/2024 1
  2010 177,773              
30 SEATTLE   I 17,500 5.00 %   Solebay Shipping Cape Company Limited, Hong Kong 1-Oct-23 15/Jul/2025 – 30/Sep/2025  
  2011 179,362              
31 P. S. PALIOS   I 27,150 5.00 %   Bohai Shipping (HEBEI) Co., Ltd 7-May-24 1/Nov/2025 – 31/Dec/2025  
  2013 179,134              
32 G. P. ZAFIRAKIS   J 17,000 5.00 %   Solebay Shipping Cape Company Limited, Hong Kong 12-Jan-23 14-Aug-24 9
  2014 179,492     26,800 5.00 %   Nippon Yusen Kabushiki Kaisha, Tokyo 16-Sep-24 16/Aug/2026 – 16/Nov/2026
33 SANTA BARBARA   J 21,250 5.00 %   Smart Gain Shipping Co., Limited 7-May-23 29/Nov/2024 – 10/Dec/2024 10,1
  2015 179,426              
34 NEW ORLEANS     20,000 5.00 %   Kawasaki Kisen Kaisha, Ltd. 7-Dec-23 15/Aug/2025 – 31/Oct/2025 10
  2015 180,960              
35 FLORIDA     25,900 5.00 %   Bunge S.A., Geneva 29-Mar-22 29/Jan/2027 – 29/May/2027 2
  2022 182,063              
4 Newcastlemax Bulk Carriers
36 LOS ANGELES   K 17,700 5.00 %   Nippon Yusen Kabushiki Kaisha, Tokyo 15-Jan-23 20-Jul-24  
  2012 206,104     28,700   20-Jul-24 1/Oct/2025 – 15/Dec/2025  
37 PHILADELPHIA   K 22,500 5.00 %   Nippon Yusen Kabushiki Kaisha, Tokyo 4-Feb-24 20/Apr/2025 – 20/Jul/2025  
  2012 206,040              
38 SAN FRANCISCO   L 22,000 5.00 %   SwissMarine Pte. Ltd., Singapore 18-Feb-23 5/Jan/2025 – 5/Mar/2025  
  2017 208,006              
39 NEWPORT NEWS   L 20,000 5.00 %   Nippon Yusen Kabushiki Kaisha, Tokyo 20-Sep-23 10/Mar/2025 – 10/Jun/2025  
  2017 208,021              
                   
* Each dry bulk carrier is a “sister ship”, or closely similar, to other dry bulk carriers that have the same letter.
** Total commission percentage paid to third parties.
*** In case of newly acquired vessel with time charter attached, this date refers to the expected/actual date of delivery of the vessel to the Company.
**** Range of redelivery dates, with the actual date of redelivery being at the Charterers’ option, but subject to the terms, conditions, and exceptions of the particular charterparty.
 
1Based on latest information.
2Bareboat chartered-in for a period of ten years.
3Charterers have agreed for any time in excess of the charter party period to pay the rate of 105% of the Baltic Panamax Index 5 TC average as published by the Baltic Exchange on a daily basis during the excess period commencing from August 20, 2024 or the vessel’s present charter party rate, whichever is higher.
4Vessel was on scheduled drydocking from August 30, 2024 until September 16, 2024.
5Redelivery date based on an estimated time charter trip duration of about 86 days.
6Currently without an active charterparty. Vessel on scheduled drydocking.
7The charter rate will be US$12,250 per day for the first 30 days of the charter period.
8Vessel has been sold and delivered to her new Owners on September 4, 2024.
9Vessel was on scheduled drydocking from August 14, 2024 until September 16, 2024.
10Bareboat chartered-in for a period of eight years.

Summary of Selected Financial & Other Data (unaudited)        
    Three months ended September 30,   Nine months ended September 30,
    2024   2023   2024   2023
                 
STATEMENT OF INCOME DATA (in thousands of US Dollars)
Time charter revenues $ 57,488   $ 62,062   $ 171,136   $ 202,082  
Voyage expenses   3,654     2,931     10,067     10,295  
Vessel operating expenses   21,239     21,202     63,372     63,965  
Net income   3,715     7,386     3,009     40,463  
Net income/(loss) attributable to common stockholders   2,272     5,944     (1,318 )   36,136  
FLEET DATA  
Average number of vessels   38.7     41.0     39.1     41.2  
Number of vessels   38.0     41.0     38.0     41.0  
Weighted average age of vessels   11.0     10.5     11.0     10.5  
Ownership days   3,561     3,772     10,723     11,240  
Available days   3,511     3,721     10,623     11,128  
Operating days   3,508     3,720     10,586     11,097  
Fleet utilization   99.9 %   100.0 %   99.7 %   99.7 %
AVERAGE DAILY RESULTS  
Time charter equivalent (TCE) rate (1) $ 15,333   $ 15,891   $ 15,162   $ 17,235  
Daily vessel operating expenses (2) $ 5,964   $ 5,621   $ 5,910   $ 5,691  
                 

Non-GAAP Measures

(1) Time charter equivalent rate, or TCE, is defined as our time charter revenues less voyage expenses during a period divided by the number of our available days during the period, which is consistent with industry standards. TCE is a non-GAAP measure, and management believes it is useful to investors because it is a standard shipping industry performance measure used primarily to compare daily earnings generated by vessels on time charters with daily earnings generated by vessels on voyage charters, because charter hire rates for vessels on voyage charters are generally not expressed in per day amounts while charter hire rates for vessels on time charters are generally expressed in such amounts. TCE is used by management to assess and compare the vessels’ profitability.
(2) Daily vessel operating expenses, which include crew wages and related costs, the cost of insurance, expenses relating to repairs and maintenance, the costs of spares and consumable stores, tonnage taxes and other miscellaneous expenses, are calculated by dividing vessel operating expenses by ownership days for the relevant period.
   

Conference Call and Webcast Information

The Company’s management will conduct a conference call and simultaneous Internet webcast to review these results at 9:00 A.M. (Eastern Time) on Monday, November 25, 2024.

Investors may access the webcast by visiting the Company’s website at www.dianashippinginc.com, and clicking on the webcast link. An accompanying investor presentation also will be available via the webcast link and on the Company’s website. The conference call also may be accessed by telephone by dialing 1-877-407-8291 (for U.S.-based callers) or 1-201-689-8345 (for international callers) and asking the operator for the Diana Shipping Inc. conference call.

A replay of the webcast will be available soon after the completion of the call and will be accessible for 30 days on www.dianashippinginc.com. A telephone replay also will be available for 30 days by dialing 1-877-660-6853 (for U.S.-based callers) or 1-201-612-7415 (for international callers) and providing the Replay ID number 13749833.

About the Company

Diana Shipping Inc. is a global provider of shipping transportation services through its ownership and bareboat charter-in of dry bulk vessels. The Company’s vessels are employed primarily on short to medium-term time charters and transport a range of dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, Company management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for dry bulk shipping capacity, changes in the Company’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Company’s vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, including risks associated with the continuing conflict between Russia and Ukraine and related sanctions, potential disruption of shipping routes due to accidents or political events, including the escalation of the conflict in the Middle East, vessel breakdowns and instances of off-hires and other factors. Please see the Company’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

(See financial tables attached)

DIANA SHIPPING INC.
FINANCIAL TABLES
Expressed in thousands of U.S. Dollars, except share and per share data
                 
UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)
 
    Three months ended September 30,   Nine months September 30,
    2024   2023   2024   2023
REVENUES:                
Time charter revenues $ 57,488   $ 62,062   $ 171,136   $ 202,082  
OPERATING EXPENSES                
Voyage expenses   3,654     2,931     10,067     10,295  
Vessel operating expenses   21,239     21,202     63,372     63,965  
Depreciation and amortization of deferred charges   11,217     11,617     33,323     38,278  
General and administrative expenses   8,384     8,909     25,113     24,604  
Management fees to a related party   333     333     999     980  
Gain on sale of vessels   (4,227 )       (5,799 )   (4,995 )
Other operating income/ (loss)   182     (703 )   (207 )   (894 )
Operating income, total $ 16,706   $ 17,773   $ 44,268   $ 69,849  
                 
OTHER INCOME / (EXPENSES):                
Interest expense and finance costs   (12,198 )   (12,837 )   (35,848 )   (36,682 )
Interest and other income   2,232     2,295     6,008     6,040  
Gain/(loss) on derivative instruments   (548 )   153     (187 )   153  
Loss on extinguishment of debt   (3,475 )       (3,475 )   (748 )
Gain on deconsolidation of subsidiary               844  
Gain/(loss) on investments   (948 )       (2,699 )   761  
Gain/ (Loss) on warrants   1,973         (4,800 )    
Gain/(loss) from equity method investments   (27 )   2     (258 )   246  
Total other expenses, net $ (12,991 ) $ (10,387 ) $ (41,259 ) $ (29,386 )
                 
Net comprehensive income $ 3,715   $ 7,386   $ 3,009   $ 40,463  
Dividends on series B preferred shares   (1,443 )   (1,442 )   (4,327 )   (4,327 )
                 
Net comprehensive income/(loss) attributable to common stockholders   2,272     5,944     (1,318 )   36,136  
                 
Earnings/(loss) per common share, basic $ 0.02   $ 0.06   $ (0.01 ) $ 0.36  
                 
Earnings/(loss) per common share, diluted $   $ 0.06   $ (0.01 ) $ 0.36  
Weighted average number of common shares outstanding, basic   119,032,441     100,721,952     114,904,876     99,241,903  
Weighted average number of common shares outstanding, diluted   120,212,686     102,481,766     114,904,876     100,672,119  
 

CONDENSED CONSOLIDATED BALANCE SHEET DATA    
(in thousands of U.S. Dollars)    
           
      September 30, 2024   December 31, 2023*

ASSETS
  (unaudited)    
           
Cash, cash equivalents, restricted cash and time deposits $ 186,805** $ 161,592**
Investments in equity securities     20,729
Other current assets   20,828   19,900
Fixed assets   888,646   924,474
Investments in related parties and equity method investments   48,200   24,087
Other noncurrent assets   16,723   15,628
Total assets $ 1,161,202 $ 1,166,410
           

LIABILITIES AND STOCKHOLDERS’ EQUITY
       
           
Long-term debt and finance liabilities, net of deferred financing costs $ 627,001 $ 642,772
Other liabilities   38,757   34,617
Total stockholders’ equity   495,444   489,021
Total liabilities and stockholders’ equity $ 1,161,202 $ 1,166,410
           
* The balance sheet data has been derived from the audited consolidated financial statements at that date.
** Includes time deposits of $35 million and $40 million as of September 30, 2024 and December 31, 2023, respectively.
   

OTHER FINANCIAL DATA (unaudited)        
    Three months ended September 30,   Nine months ended September 30,
    2024   2023   2024   2023
                 
Net cash provided by operating activities $ 19,203 $ 20,060   $ 68,386   $ 72,615  
Net cash provided by/(used in) investing activities   4,501   (11,980 )   (9,123 )   (6,108 )
Net cash provided by/(used in) financing activities $ 8,060 $ (42,145 ) $ (29,050 ) $ (54,383 )
                       



Corporate Contact:
Ioannis Zafirakis
Director, Chief Financial Officer, Chief Strategy Officer, Treasurer and Secretary
Telephone: + 30-210-9470100
Email: [email protected]
Website: www.dianashippinginc.com
X: @Dianaship

Investor and Media Relations:
Edward Nebb
Comm-Counsellors, LLC
Telephone: + 1-203-972-8350
Email: [email protected]

Stadium Capital Management Issues Letter to Sleep Number Shareholders Regarding the Need for a Reconstituted Board and Independent CEO Search

Stadium Capital Management Issues Letter to Sleep Number Shareholders Regarding the Need for a Reconstituted Board and Independent CEO Search

Calls on Sleep Number to Collaborate with its Largest Shareholder to Add New Directors to the Board, Appoint an Executive Chairman and Ensure a Wholly Independent CEO Search Process to Identify the Company’s Next Leader

Encourages Shareholders to Make Their Concerns with Sleep Number’s Unacceptable Performance and Self-Preservation Tactics Known by Communicating Them to the Company

Intends to Nominate Exceptionally Qualified Directors Should the Board Remain Unwilling to Work with Stadium on Changes Necessary to Unlock the Tremendous Value Trapped in Sleep Number’s Shares

NEW CANAAN, Conn.–(BUSINESS WIRE)–
Stadium Capital Management, LLC today sent the below letter to shareholders of Sleep Number Corporation (NASDAQ: SNBR).

***

November 25, 2024

Fellow Sleep Number Shareholders:

Stadium Capital Management, LLC (together with certain of its affiliates, “Stadium Capital” or “we”) is the largest shareholder of Sleep Number Corporation (“Sleep Number” or the “Company”), owning approximately 11.7% of the Company’s outstanding shares. We hold our position because we remain convinced that there is enormous upside in the value of the Company if certain fundamental changes occur.

Our successful and nearly three-decade investment strategy is typically based on close, friendly collaboration with our concentrated portfolio of companies, anchored in deep research and a long-term investment horizon. We strongly prefer to keep engagement private and are nothing if not patient, but after a decade of diligent work on Sleep Number and over 15 meetings with the Company’s management and Board of Directors (the “Board”), our frustration with current leadership, who has overseen massive shareholder value destruction, reached a tipping point last year. As a result, we were compelled to take the rare step of publicly expressing our concerns regarding Sleep Number’s leadership and governance last year.1 This ultimately led to the appointment of two highly qualified new directors to the Board pursuant to a Cooperation Agreement between Stadium Capital and the Company (the “Cooperation Agreement”).

On October 30, 2024, a mere four days before our one-year Cooperation Agreement expired, the Board announced several management and governance changes, including the retirement of the CEO, President and Chair of the Board, Shelly Ibach, and a gradual de-classification and shrinking of the Board. While on the surface these changes represent forward progress, it is clear to us that they are the bare minimum, insufficient and wholly inadequate given the gravity and urgency of the situation Sleep Number finds itself in today – thanks to this Board. In our view, these changes reflect the current Board’s efforts to cling to the status quo and maintain control.

Now, Sleep Number’s shareholders are being asked to entrust this Board to hire the Company’s next CEO, which is, without any doubt, the most critical decision facing the Company over the next decade. Given that these are the same directors who have overseen massive value destruction and failed to hold Ms. Ibach accountable for far too long, shareholders cannot trust the Board as currently constructed to get this decision right, a decision that will define the future of Sleep Number.

Before deciding to make our concerns public, we worked tirelessly and in good faith to persuade the Board to collaborate privately with us to improve its flawed CEO search process. As with most of our suggestions, the Board summarily rejected our proposals. While shareholders cannot trust the current Board to hire Sleep Number’s next CEO, we also believe that shareholders cannot trust this Board, which is still populated with many long-tenured directors who presided over a truly colossal destruction of shareholder value, to oversee the crucial capital allocation decisions facing the Company. A meaningfully reconstituted Board will be better positioned to identify a great CEO, create the best incentives for that CEO and instill long overdue accountability into Sleep Number’s corporate culture, all of which would help unlock the tremendous value that exists within this Company. It is well past time to put an end to this relentless and extraordinary value destruction, and fix Sleep Number’s leadership and governance.

We have spoken to many Sleep Number shareholders following the filing of our Schedule 13D on November 4, 2024 and the feedback we received was unanimous – more and urgent change is desperately needed. We are urging our fellow shareholders to express their views directly to the Board, whether publicly or privately, so the Board can grasp just how widespread shareholder dissatisfaction remains. For those shareholders with whom we have not already spoken, please know that our line is open and we welcome the opportunity to hear your thoughts as well.

Significant Value Destruction Underscores the Urgent Need for Shareholder-Driven Change

The immense shareholder value destruction that has occurred at Sleep Number makes blatantly obvious the need for real change at the Company. Sleep Number has been a serial underperformer, both in absolute and relative terms, over any relevant measurable period during Ms. Ibach’s tenure. The table below includes total shareholder returns for various time periods compared to Sleep Number’s closest peer, Tempur Sealy International, Inc. (“Tempur Sealy”). The performance disconnect between two direct competitors is staggering and indisputable.2

Total Return Data (as of 11/22/2024)

Ibach

1-year

3-year

5-year

10-year

Tenure

Sleep Number Corporation

23%

-85%

-74%

-52%

-52%

Tempur Sealy International, Inc.

40%

29%

172%

311%

430%

 

Relative Underperformance

-17%

-114%

-246%

-364%

-482%

This comparison to Sleep Number’s closest peer is starkly informative because Tempur Sealy went through a shareholder-driven leadership change in 2015. Consider the performance results between Tempur Sealy and Sleep Number before and after this change:3

Total Return Data

Pre-Change

Post-Change

Sleep Number Corporation.

24%

-61%

Tempur Sealy International, Inc.

29%

311%

 

Relative Underperformance

-5%

-372%

During Ms. Ibach’s tenure, the Board has unequivocally failed in its two primary responsibilities: (i) ensuring the Company hires, incentivizes and holds accountable the right CEO, and (ii) allocating capital.4 It is time for real change.

We believe that corporate governance improvements and shareholder-driven reform can make a big difference.

Recent Governance Changes are Insufficient

It is clear to us (and the many shareholders we have spoken with) that the recent changes announced by the Company are insufficient. Sleep Number is on a path to de-classify the Board, separate the Chair and CEO roles and slowly shrink the Board. Normally, we would applaud these moves, as it would signal that a board has committed to better governance by making itself more independent from management and more accountable to shareholders.

In this case, however, these corporate governance “improvements” should be viewed as wholly inadequate self-preservation measures. The below provides some relevant context:

What the Board Says:5

The Reality:

“These changes reflect the Board’s ongoing commitment to progressive and effective corporate governance and accountability to shareholders.”

After almost a year of inaction, Sleep Number waited until two business days before the expiration of the Cooperation Agreement to announce these changes. We have suggested that the Board implement these standard, common sense governance practices for over a year, and many of these changes should have been implemented at the Company’s 2024 Annual Meeting of Shareholders.

 

The Company advised us that this year’s class of directors will yet again be nominated for three-year terms, meaning that the declassification process will not actually begin until 2026.

 

 

“While we value the contributions of each of our talented directors, we believe that strategically reducing the size of the Board at the appropriate time will enhance our governance.”

The Board has not committed to an accelerated departure date for Stephen Gulis or Brenda Lauderback. The Board’s claim that time is needed to transition committee chair roles is an absurd excuse. These over-tenured, under-performing directors who have served on the Board since 2005 and 2004, respectively, should never have been nominated for re-election in 2024 in the first place.

 

Sleep Number’s directors are cumulatively paid almost 50% more than those of Tempur Sealy despite the Company having 3% the market capitalization and revenue that is 40% lower. On top of this, Sleep Number’s former Chairman, who departed the Board in May 2023, continued to receive director fees through the first three quarters of 2024.6

 

In our view, this extended transition has not only been costly to shareholders, but it is also insulting to all Sleep Number employees who have suffered pay cuts and/or lost their jobs as part of urgent cost-cutting initiatives. The long-tenured directors on the Board – the people as responsible for this harm as anyone – have not been held accountable.

 

 

 

“The Board has unanimously determined its intent to appoint Michael Harrison as independent Chair following the 2025 Annual Meeting.”

The Board’s choice of a new Chair is totally unacceptable and suggests that, collectively, the current directors do not understand the importance of moving on from the disastrous Ibach era. Sleep Number has several more highly qualified, shorter-tenured directors with fewer ties to the failed Ibach era who are clearly more appropriate for the role.

The Current CEO Search Process is Flawed

We have spoken with a large and diverse group of market and industry participants to gather perspectives regarding Sleep Number and its CEO search. The overwhelming consensus is that, to be successful, a search process must be fully and unequivocally independent from the outgoing CEO.

In recent conversations with the Board, we learned several deeply concerning facts. First, Ms. Ibach was involved in drafting the specifications for her successor and will interview the candidates. Second, the executive search team leading the process has close ties to the Ibach era, having led past searches for directors and senior leadership roles. Finally, and perhaps most disturbingly, social media activity indicates that the executive search partner leading this search appears to have a close relationship with Ms. Ibach. Given these dynamics, it is impossible to believe this process is truly independent of Ms. Ibach.

We would note that the current process might indeed be appropriate in a situation where a successful CEO is retiring. At Sleep Number, however, the Board is replacing a CEO whose failed leadership of the Company resulted in significant underperformance and massive value destruction during her lengthy tenure. Successful succession planning in this case requires an acknowledgement of past failings and a clean break from the past. While this is completely obvious to all market participants with whom we engaged, somehow, the Board does not seem to understand this.

This Board Cannot be Trusted to Hire Sleep Number’s Next CEO

How big a failure was the Ibach era? Operationally, from 2012 to 2024, Sleep Number’s unit market share did not increase despite increasing the store count by almost 60%, increasing the advertising budget by more than 50% and deploying hundreds of millions of dollars into R&D and technology acquisition. Margins consistently fell short of expectations. The Company began the Ibach era with over $175 million in excess cash, generated over $800 million in free cash flow and paid zero dividends during Ms. Ibach’s tenure.7 Sleep Number’s market capitalization is currently less than $300 million and its stock is down an astonishing 91% from its peak.8

The Chair of the Management Development and Compensation Committee (Ms. Lauderback) – the committee chartered with succession planning and thus leading the CEO search – has been on the Board for over 20 years. The incoming Board Chair (Mr. Harrison), who also sits on the search committee, has been on the Board for the entirety of, and thus enabled, Ms. Ibach’s nearly 13-year tenure as CEO. One other search committee member (Deborah Kilpatrick) has been on the Board for over six years and regularly lavishes public praise on Ms. Ibach. Another director up for re-election this year (Barbara Matas) has stridently expressed her great admiration for Ms. Ibach, insisting on a call this past spring to us that Ms. Ibach “is going to be our CEO” and that shareholders had better accept that. In the face of overwhelming and completely damning evidence, the Board simply refuses to see the obvious – Sleep Number urgently needs a clean break from the failed Ibach era.

On November 12, 2024, we made a proposal to the Company that was intended to be a non-disruptive and collaborative solution to the current situation.9 We offered to support the Board at the Company’s upcoming annual meeting if the Board committed to a truly independent CEO search process that excluded Ms. Ibach and either changed the search committee structure or formally involved a Stadium Capital principal in the process. The Board rejected this non-escalatory, constructive proposal on the grounds that changing the committee purportedly would disrupt the ongoing process. Given Sleep Number’s poor governance and the fact that, as the Company’s largest shareholder, we had expressed that the Board does not have our support absent these kinds of changes, we thought this proposal would improve the process, expand the pool of interested and qualified candidates, and potentially satisfy other shareholders who were apparently considering raising their own concerns publicly. The Board’s grave miscalculation in rejecting our recent proposal confirmed for us that shareholders, the true owners of the Company, need more and substantive change, now.

THE path forward

Sleep Number should collaborate with its largest shareholder to refresh the Board and ensure the CEO search process is completely independent.

We are already aware of at least two highly qualified potential CEO candidates who were reluctant to get involved because of Sleep Number’s ineffective and dysfunctional Board. That is extremely concerning to us, as it should be to all owners. We are calling on the Board to collaborate with us immediately to refresh the Board and improve the CEO search process. Time is of the essence. Our suggested path forward is as follows:

  • Announce the immediate retirement of Mr. Gulis and Ms. Lauderback from the Board.

  • Replace incoming Chairman Harrison and Ms. Matas with a Stadium Capital principal and another highly qualified independent director.

  • Reconstitute the CEO search committee by fully excluding Ms. Ibach from the process, shifting the composition towards shorter-tenured directors with public company CEO experience and including a Stadium Capital principal.

  • Appoint an Executive Chairman to help run the Company during Ms. Ibach’s transition period. If one of the current qualified and relatively short-tenured Sleep Number directors is willing to fill this role, they would have our support. If there is no internal candidate, we can provide a ready, willing and highly capable external candidate.

It is nonsensical for shareholders and offensive to Sleep Number’s employees for the Board to continue wasting shareholder money to pay advisors to “defend” the Board against an outcome that owners prefer during this critical period of cost-cutting. To reiterate, if our fellow shareholders agree with our views, we encourage you to express that to the Board in short order. If the Board listens to its business owners’ views, we see a quick path to creating an excellent Board that will be capable of hiring an outstanding CEO for Sleep Number and all its stakeholders.

Should our requests and concerns continue to fall on deaf ears, we will be compelled to nominate several exceptionally qualified directors for election at Sleep Number’s 2025 Annual Meeting of Shareholders. We believe that a large portion of the Company’s shareholders would support our efforts. While a protracted public battle may potentially delay the CEO transition, we are confident that the eventual result of our successful campaign would be a high integrity search process, the hiring of the best possible CEO and an improved Board. With these elements in place at Sleep Number, we believe shareholders will be positioned to realize enormous upside over the next several years, and all stakeholders will benefit from a healthier culture based on accountability. We know what is possible at Sleep Number, which is why we are committed to taking the necessary actions for the Company to make good on its immense potential.

Sincerely,

The Investment Committee of Stadium Capital Management LLC

***

1https://www.businesswire.com/news/home/20230913488935/en/Stadium-Capital-Management-Issues-Letter-to-Sleep-Number%E2%80%99s-Board-of-Directors-Regarding-the-Urgent-Need-for-Shareholder-Driven-Change

2 Source of share price performance data used throughout is Capital IQ.

3The pre-change period is from June 1, 2012 (the start of Ms. Ibach’s tenure) to February 16, 2015, the day H Partners Management initiated a campaign that led to shareholder-driven board and CEO change at Tempur Sealy. The post-change period is from February 16, 2015 to November 22, 2024.

4 Many of these mistakes are highlighted in our 2023 letter to the Board.

5https://www.sec.gov/Archives/edgar/data/827187/000082718724000087/a2024-q3ex991skyway.htm

6 Company Securities and Exchange Commission filings.

7 Company Securities and Exchange Commission filings.

8 As of November 22, 2024.

9 Feel free to reach out to us if you would like a copy of this letter.

Longacre Square Partners

Greg Marose / Charlotte Kiaie, 646-386-0091

[email protected] / [email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Home Goods Other Retail Retail Professional Services Other Professional Services

MEDIA:

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint

Final Protocol submission on track for December, supporting initiation of Phase 3 registrational trial in Q1 2025

LAWRENCEVILLE, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the outcome of its recent End-of-Phase 2 in-person meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of its investigational interleukin-12 (IL-12) immunotherapy IMNN-001 for the treatment of advanced ovarian cancer into a Phase 3 pivotal study. IMUNON remains on track to initiate the 500-patient Phase 3 trial in the first quarter of 2025.

“The collaborative End-of-Phase 2 meeting with the FDA represents another important milestone in our IMNN-001 clinical program, and we are very pleased that the Agency is aligned with the potential for IMNN-001 to address a significant unmet need in ovarian cancer treatment and our Phase 3 plans,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “We are encouraged by the robust safety and efficacy data from our Phase 2 OVATION 2 Study, including the positive survival results recently presented in a late-breaking session at the SITC Annual Meeting. IMNN-001 is the first immunotherapy to achieve a clinically effective response in ovarian cancer, including benefits in both progression-free and overall survival in frontline treatment.”

“Our goal is to replicate these remarkable results in a Phase 3 trial, which would be transformative for the current standard of care, substantially improving overall survival and giving hope to thousands of women with advanced ovarian cancer who continue to experience disease progression,” Dr. Lindborg added.

The interaction with the FDA included an extensive review of data generated to date, including positive results from the recently completed Phase 2 OVATION 2 Study, which assessed IMNN-001 (100 mg/m2 administered intraperitoneally weekly) plus neoadjuvant and adjuvant chemotherapy (NACT) of paclitaxel and carboplatin compared to standard-of-care NACT alone in 112 patients with newly diagnosed advanced ovarian cancer. The OVATION 2 Study results demonstrated that IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in approximately a one-year (35%) improvement in overall survival compared to treatment with standard-of-care chemotherapy alone. Treatment was also generally well tolerated, with no reports of cytokine release syndrome or any other serious immune related adverse events.

About IMNN-001 Immunotherapy

Designed using IMUNON’s proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by persistent, local secretion of the IL-12 protein. IL-12 is one of the most active cytokines for the induction of potent anticancer immunity acting through the induction of T-lymphocyte and natural killer cell proliferation. IMUNON previously reported positive safety and encouraging Phase 1 results with IMNN-001 administered as monotherapy or as combination therapy in patients with advanced peritoneally metastasized primary or recurrent ovarian cancer and completed a Phase 1b dose-escalation trial (the OVATION 1 Study) of IMNN-001 in combination with carboplatin and paclitaxel in patients with newly diagnosed ovarian cancer.

About Epithelial Ovarian Cancer

Epithelial ovarian cancer is the sixth deadliest malignancy among women in the U.S. There are approximately 20,000 new cases of ovarian cancer every year and approximately 70% are diagnosed in advanced Stage III/IV. Epithelial ovarian cancer is characterized by dissemination of tumors in the peritoneal cavity with a high risk of recurrence (75%, Stage III/IV) after surgery and chemotherapy. Since the five-year survival rates of patients with Stage III/IV disease at diagnosis are poor (41% and 20%, respectively), there remains a need for a therapy that not only reduces the recurrence rate, but also improves overall survival. The peritoneal cavity of advanced ovarian cancer patients contains the primary tumor environment and is an attractive target for a regional approach to immune modulation.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101). IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.


Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing for commencement of a Phase 3 trial of IMNN-001, the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure of conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

Media Investors
CG Life ICR Healthcare
Jenna Urban Peter Vozzo
212-253-8881 443-213-0505

[email protected]
 

[email protected]
 



Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

SAN DIEGO–(BUSINESS WIRE)–
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference in Miami on Wednesday, December 4, 2024 at 11:15 a.m. ET.

An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.

About Contineum Therapeutics

Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of disease. Contineum has a pipeline of internally-developed programs to address multiple NI&I disorders. Contineum has two drug candidates in clinical trials, PIPE-791, an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307, a selective inhibitor of the M1 receptor in clinical development for relapsing-remitting multiple sclerosis. PIPE-307 is being developed pursuant to a global license and development agreement between Contineum and Janssen Pharmaceutica NV, a Johnson & Johnson company, who has also announced plans to initiate a Phase 2 trial of PIPE-307 in depression in 2024. For more information, please visit www.contineum-tx.com.

Steve Kunszabo

Contineum Therapeutics

Senior Director, Investor Relations & Corporate Communications

858-649-1158

[email protected]

KEYWORDS: United States North America California Florida

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Neurology

MEDIA:

Logo
Logo

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

Attributes 234% Revenue Growth to Operational Excellence and Strong Commercial Execution

CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 30th year. The 2024 Deloitte Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023, for which Catalyst grew 234% during this period.

Catalyst’s President and Chief Executive Officer, Richard J. Daly, credits the team’s operational excellence and strong commercial execution for the 234% revenue growth. He said, “It’s an honor to be recognized as one of the fastest-growing companies in North America across industry sectors. We remain confident in our ability to execute against our strategy, which includes capitalizing on new opportunities to broaden our rare orphan portfolio with innovative and differentiated products, and we remain steadfast in enhancing our growth potential while prioritizing the needs of our patient communities.”

“For 30 years we’ve been celebrating companies that are actively driving innovation. The software industry continues to be a beacon of growth, and the fintech industry made a strong showing on this year’s list, surpassing life sciences for the first time,” said Steve Fineberg, Vice Chair, U.S. technology sector leader, Deloitte. “Significantly, we also saw a breakthrough in performance of private companies, with the highest number of private companies named to the list in our program’s history. This year’s winners have shown they have the vision and expertise to continue to perform at a high level, and that deserves to be celebrated.”

“Innovation, transformation and disruption of the status quo are at the forefront for this year’s Technology Fast 500 list, and there’s no better way to celebrate 30 years of program history,” said Christie Simons, Partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s Audit & Assurance practice. “This year’s winning companies have demonstrated a continuous commitment to growth and remarkable consistency in driving forward progress. We extend our congratulations to all of this year’s winners — it’s an incredible time for innovation.”

Overall, 2024 Technology Fast 500 companies achieved revenue growth ranging from 201% to 153,625% over the three-year time frame, with an average growth rate of 1,981% and median growth rate of 460%.

About the 2024 Deloitte Technology Fast 500

Now in its 30th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2020 to 2023.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US $50,000, and current-year operating revenues of at least US $5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Catalyst Pharmaceuticals        
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America’s most successful small-cap companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

About Deloitte

Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world’s most admired brands, including nearly 90% of the Fortune 500® and more than 8,500 U.S.-based private companies. At Deloitte, we strive to live our purpose of making an impact that matters by creating trust and confidence in a more equitable society. We leverage our unique blend of business acumen, command of technology, and strategic technology alliances to advise our clients across industries as they build their future. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Bringing more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte’s approximately 460,000 people worldwide connect for impact at www.deloitte.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.



Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]  

Media Contact
David Schull, Russo Partners
(858) 717-2310
[email protected]

Safe Pro’s Airborne Response Awarded Purchase Order for Drone Aerial Inspections of Telecom Towers in South Florida

Safe Pro’s Airborne Response Awarded Purchase Order for Drone Aerial Inspections of Telecom Towers in South Florida

Q4 2024 Drone Services Revenue Increasing, Driven by Completion of Over 500 Miles of Critical Power Infrastructure Inspections Following Hurricane Milton

AVENTURA, Fla.–(BUSINESS WIRE)–
Safe Pro Group Inc. (Nasdaq: SPAI) (“Safe Pro” or the “Company”), a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing, today announced that its Mission Critical Unmanned Solutions® subsidiary, Airborne Response (Airborne), has received a purchase order for a multi-site drone inspection project to be executed in 2025 from a multinational telecommunications firm (the “telecommunications customer”).

Under the terms of the purchase order, Airborne’s uncrewed aircraft systems (UAS) teams will conduct enhanced drone-based aerial inspections and asset management services on behalf of the telecommunications customer. Airborne Response will perform aerial inspections utilizing Skydio, Inc. drones to inspect multiple radio towers used by a municipal South Florida fire & rescue department.

“This award further demonstrates the trust our customers place in our Airborne Response business unit to monitor and ensure the reliability of Florida’s critical infrastructure,” said Dan Erdberg, Chairman and CEO of Safe Pro Group. “Highlighted by the recent completion of over 500 miles of powerline inspections for Florida’s largest electric utility following hurricane Milton, we are pleased by the strong growth in our drone services business in the fourth quarter and look forward to supporting the needs of our customers in 2025.”

Airborne Response customers include leading energy, telecommunications, and insurance firms across Florida. Its flight teams utilize sUAS to help assess the condition of Florida’s power grid and evaluate storm damage to residences. Its emergency drone flight crews were recently deployed by multiple Florida enterprise customers to support the massive hurricane Milton recovery efforts.

A video introduction to Safe Pro Groups business units can be found here.

For more information about Airborne Response, please visit airborneresponse.com. If you are a remote pilot available for work, please visit pilots.airborneresponse.com and if you are interested in purchasing a Skydio system or have questions about adding drones to your operations, you can contact Airborne’s team of drone specialists at https://airborneresponse.com/skydio-reseller-new-form/.

To learn more about Safe Pro Group, its subsidiaries, and technologies, please visit https://safeprogroup.com and connect with us on LinkedIn, Facebook and X.

About Safe Pro Group Inc.

Safe Pro Group is a leading provider of artificial intelligence (AI) solutions specializing in drone imagery processing leveraging commercially available “off-the-shelf” drones with its proprietary machine learning and computer vision technology to enable rapid identification of explosives threats, providing a much safer and more efficient alternative to traditional human-based analysis methods. Built on a cloud-based ecosystem and powered by Amazon Web Services (AWS), Safe Pro Group’s scalable platform is targeting multiple markets that include commercial, government, law enforcement and humanitarian sectors where its Safe Pro AI software, Safe-Pro USA protective gear and Airborne Response drone-based services can work in synergy to deliver safety and operational efficiency. For more information on Safe Pro Group Inc., please visit https://safeprogroup.com/.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements relate to future events, future expectations, plans and prospects. Although Safe Pro Group believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Safe Pro Group has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (the “SEC”), copies of which may be obtained from the SEC’s website at www.sec.gov. Any forward-looking statements contained in this press release speak only as of its date. Safe Pro Group undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Media Relations for Safe Pro Group Inc.:

[email protected]

Investor Relations for Safe Pro Group Inc.:

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Software Internet Hardware Robotics Data Management Technology Drones Defense Artificial Intelligence Government Technology Air Transport Telecommunications

MEDIA:

Logo
Logo

STMicroelectronics Announces Status of Common Share Repurchase Program

STMicroelectronics Announces Status of

Common Share Repurchase Program


Disclosure of Transactions in Own Shares – Period from Nov 18, 2024 to Nov 22, 2024

AMSTERDAM – November 25, 2024 — STMicroelectronics N.V. (the “Company” or “STMicroelectronics”), a global semiconductor leader serving customers across the spectrum of electronics applications, announces full details of its common share repurchase program (the “Program”) disclosed via a press release dated June 21, 2024. The Program was approved by a shareholder resolution dated May 22, 2024 and by the supervisory board.

STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris, in the period between Nov 18, 2024 to Nov 22, 2024 (the “Period”), of 468,800 ordinary shares (equal to 0.05% of its issued share capital) at the weighted average purchase price per share of EUR 23.2951 and for an overall price of EUR 10,920,729.99.

The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes, or other allocations of shares, to employees or to members of the administrative, management or supervisory bodies of the issuer or of an associate company.

The shares may be held in treasury prior to being used for such purpose and, to the extent that they are not ultimately needed for such purpose, they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.

Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STMicroelectronics (ISIN: NL0000226223), in detailed form.

Transactions in Period

Dates of transaction Number of shares purchased Weighted average purchase price per share (EUR) Total amount paid (EUR) Market on which the shares were bought (MIC code)
18-Nov-24 106,500 23.8398 2,538,938.70 XPAR
19-Nov-24 89,500 23.2365 2,079,666.75 XPAR
20-Nov-24 90,800 23.1068 2,098,097.44 XPAR
21-Nov-24 91,000 22.8518 2,079,513.80 XPAR
22-Nov-24 91,000 23.3463 2,124,513.30 XPAR
Total for Period 468,800 23.2951 10,920,729.99  

Following the share buybacks detailed above, the Company holds in total 13,045,041 treasury shares, which represents approximately 1.4% of the Company’s issued share capital.

In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).

About STMicroelectronics

At ST, we are over 50,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are committed to achieving our goal to become carbon neutral on scope 1 and 2 and partially scope 3 by 2027. Further information can be found at www.st.com.

For further information, please contact:

INVESTOR RELATIONS:
Jérôme Ramel
EVP Corporate Development & Integrated External Communication
Tel: +41.22.929.59.20
[email protected]

MEDIA RELATIONS:
Alexis Breton        
Corporate External Communications
Tel: +33.6.59.16.79.08


[email protected]

Attachment



Graphjet Technology Receives ISO Certifications for Sustainable Graphite and Graphene Production; Strengthens IP Position

Secures three ISO certifications for the eco-friendly manufacturing of graphite and graphene from biomass waste

Awarded patent further enhances competitive moat in the production of green graphite and graphene from palm kernel shells

KUALA LUMPUR, Malaysia, Nov. 25, 2024 (GLOBE NEWSWIRE) — Graphjet Technology (“Graphjet” or “the Company”) (Nasdaq:GTI), a leading manufacturing company focusing on carbon-based materials, producing artificial graphite from biomass waste residues from the process of palm oil, today announced the Company has received ISO (International Organization for Standardization) certifications for the manufacturing of graphite and graphene from biomass waste from ARES International, a verification services provider.

The scope of the ISO certifications covered the manufacturing of biomass waste (palm kernel shell and composite material) to produce artificial graphite and graphene:

  • ISO 14001:2015
  • ISO 9001:2015
  • ISO 45001:2018

These ISO certifications showcase Graphjet Technology’s commitment to excellence in environmental, quality, and health & safety management, which is expected to drive operational, financial, and reputational gains. The certifications also demonstrate that the Company compliance is in line with global standards and are expected to enhance its reputation and improve its market access, customer satisfaction and loyalty, cost efficiency and sustainability, and operational efficiency.

“On the heels of opening the world’s first and largest green graphite facility, receiving these ISO certifications is a testament to the strength of our patented technology,” said Aiden Lee, CEO and Co-Founder of Graphjet. “These certifications provide third-party validation of our technology and demonstrate to our customers and other stakeholders the opportunities ahead for our green graphite production process. As we continue to scale, we aim to meet the growing demand for this strategic material in semiconductors and electric vehicle batteries.”

Awarded Key Graphene Patent

In addition, Graphjet has been granted an important patent in Malaysia, further solidifying its industry-leading position in the production of green graphite and graphene. The patent, which builds on Graphjet’s existing IP protection for palm-based synthetic graphite production, covers the company’s unique and innovative process for producing palm-based graphene. It is the only patent of its kind in Malaysia. The Company is also pursuing patents in the United States to expand its leading global IP position.

“We are pleased to have been granted a significant patent for our graphene production process. This achievement further fortifies our leading IP position in the global graphite and graphene industries,” continued Aiden Lee.

Graphjet’s patented, sustainable and cost-effective technology produces green graphite directly from palm kernel shells. This technology reduces the Company’s operational carbon footprint by up to 83% and reduces costs by up to 80% compared to traditional processes. Per kg of graphite produced, Graphjet produces only 2.95 kg CO2 emissions, compared to 16.8 kg CO2 emissions and 17 kg CO2 emissions from natural and synthetic graphite production, respectively, in China. Graphjet’s technology is expected to have the lowest carbon footprint of any graphite production process in the world.

About Graphjet Technology Sdn. Bhd.
Graphjet Technology Sdn. Bhd. (Nasdaq: GTI) was founded in 2019 in Malaysia as an innovative graphene and graphite producer. Graphjet Technology has the world’s first patented technology to recycle palm kernel shells generated in the production of palm seed oil to produce single layer graphene and artificial graphite. Graphjet’s sustainable production methods utilizing palm kernel shells, a waste agricultural product that is common in Malaysia, will set a new shift in graphite and graphene supply chain of the world. For more information, please visit https://www.graphjettech.com/.

Cautionary Statement Regarding Forward-Looking Statements

The information in this press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “aim,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) changes in the markets in which Graphjet competes, including with respect to its competitive landscape, technology evolution or regulatory changes; (ii) the risk that Graphjet will need to raise additional capital to execute its business plans, which may not be available on acceptable terms or at all; (iii) Graphjet is beginning the commercialization of its technology and it may not have an accurate estimate of future capital expenditures and future revenue; (iv) statements regarding Graphjet’s industry and market size; (v) financial condition and performance of Graphjet, including the anticipated benefits, the implied enterprise value, the financial condition, liquidity, results of operations, the products, the expected future performance and market opportunities of Graphjet; (vi) Graphjet’s ability to develop and manufacture its graphene and graphite products; and (vii) those factors discussed in our filings with the SEC. You should carefully consider the foregoing factors and the other risks and uncertainties that will be described in the “Risk Factors” section of the documents to be filed by Graphjet from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward- looking statements, and while Graphjet may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. Graphjet does not give any assurance that Graphjet will achieve its expectations.

Graphjet Technology Contacts

Investors
[email protected]

Media
[email protected]



Vast Receives $30M from Australian Renewable Energy Agency for Green Technology to Decarbonise Australia’s Grid and Power Green Fuels Production

SYDNEY, Nov. 25, 2024 (GLOBE NEWSWIRE) — Vast Renewables Limited (“Vast”) (Nasdaq: VSTE) today announced it has signed an updated funding agreement to access up to $30 million of its existing $65 million grant from the Australian Renewable Energy Agency (“ARENA”). The funding will support Vast’s green technology manufacturing and project development activities as it deploys its next generation concentrated solar thermal power (CSP) solution to deliver the clean, dispatchable power and heat that the world needs.

CSP is an obvious technology to deploy in Australia’s energy transition in one of the sunniest countries on earth. By capturing and storing the sun’s energy as heat, CSP can power homes, industry and transport with green, reliable and affordable energy. The technology’s dispatchable capacity will be a critical complement to intermittent solar PV and wind in Australia’s energy mix, delivering longer-lasting power that’s cost effective when the sun isn’t shining and the wind isn’t blowing.

Vast has pioneered the next generation of proprietary CSP technology, promising superior performance at lower cost and risk. It has a global pipeline of projects that will help to decarbonise electricity generation and power the production of green methanol and sustainable aviation fuels. Proven at its grid-connected pilot project in New South Wales, Vast’s leading technology is set to be deployed at utility-scale at Vast Solar 1 (“VS1”), a 30MW power plant with 8 hours of storage located in the Port Augusta Green Energy Hub, South Australia.

Vast’s Port Augusta utility-scale CSP project will generate clean, dispatchable electricity which will be sold into the National Electricity Market, and it will help to power a world-first co-located green methanol production facility, Solar Methanol 1 (“SM1”), also being developed by Vast. A real world, in-demand application for hydrogen, green methanol has the potential to decarbonise shipping and is already being used to power major container vessels.

Vast’s internationally awarded, Australian-made technology is currently produced at its Queensland facility. ARENA’s funding will see Vast scale up its Australian green technology manufacturing to supply VS1 and future projects. The $30 million funding will also support Vast in the final project development activities ahead of Final Investment Decision (FID) on VS1 in early 2025. Vast’s Australian projects and manufacturing facility are anticipated to create dozens of green manufacturing and construction jobs, and long-term plant operations roles.

The support of the Australian Government has been key for Vast, which has the potential to be a catalyst for a domestic CSP industry and expects to export its green technology around the world to its global pipeline of projects, according to Vast CEO Craig Wood.

Wood said, “Unlocking this funding helps accelerate our Australian green technology manufacturing and the final stages of development for our first utility-scale project. ARENA’s backing has been pivotal, getting us to a point where we are garnering significant interest from investors, industry and international governments keen to explore how our technology can play a key role in decarbonising hard-to-abate sectors including electricity, industry and fuels.

“With the continued support of the Australian Government and our investors, we are looking forward to building our next projects, and to helping Australia become an export powerhouse for this next generation of green technology.”

The $30 million non-dilutive grant will be released from $65 million of funding announced in February 2023 by the Minister for Climate Change and Energy, Hon Chris Bowen MP, and ARENA. Construction of VS1 is anticipated to begin in Q2 2025, with capital expenditures estimated to be in the range of AUD360 million – AUD390 million.

Vast’s 1.1MW demonstration project in Forbes, New South Wales

About Vast 
Vast is a renewable energy company that has CSP systems to generate, store, and dispatch carbon-free, utility-scale electricity, industrial heat, or a combination to enable the production of green fuels. Vast’s CSP v3.0 approach utilises a proprietary, modular sodium loop to efficiently capture and convert solar heat into these end products. 

On December 19, 2023, Vast listed on the Nasdaq under the ticker symbol “VSTE”, while remaining headquartered in Australia. 

Visit www.vast.energy for more information.

Contacts 
For Investors: 
Caldwell Bailey 
ICR, Inc. 
[email protected] 

For US media: 
Matt Dallas 
ICR, Inc. 
[email protected] 

For Australian media: 
Nick Albrow 
Wilkinson Butler 
[email protected] 

Forward Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included herein, regarding VS1, Vast’s future financial performance, Vast’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management are forward-looking statements. When used herein, including any oral statements made in connection herewith, the words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “project,” “should,” “will,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on Vast management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, Vast disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. Vast cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Vast. These risks include, but are not limited to, general economic, financial, legal, political and business conditions and changes in domestic and foreign markets; Vast’s ability to obtain financing on commercially acceptable terms or at all; Vast’s ability to manage growth; Vast’s ability to execute its business plan, including the completion of the Port Augusta project (including VS1), at all or in a timely manner and meet its projections; potential litigation, governmental or regulatory proceedings, investigations or inquiries involving Vast, including in relation to Vast’s recent business combination; the inability to recognize the anticipated benefits of Vast’s recent business combination; costs related to that business combination; changes in applicable laws or regulations and general economic and market conditions impacting demand for Vast’s products and services. Additional risks are set forth in the section titled “Risk Factors” in the Annual Report on Form 20-F for the year ended June 30, 2024, dated September 9, 2024, as amended on November 7, 2024, and other documents filed, or to be filed with the SEC by Vast. Should one or more of the risks or uncertainties described herein and in any oral statements made in connection therewith occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Additional information concerning these and other factors that may impact Vast’s expectations can be found in Vast’s periodic filings with the SEC. Vast’s SEC filings are available publicly on the SEC’s website at www.sec.gov

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/943211e9-90bd-492d-b33b-c3c83fb5ebc5